...
首页> 外文期刊>Infectious Diseases and Therapy >Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review
【24h】

Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review

机译:施用到前9152的治疗报告的Covid-19案件:系统审查

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The emergence of SARS-CoV-2/2019 novel coronavirus (COVID-19) has created a global pandemic with no approved treatments or vaccines. Many treatments have already been administered to COVID-19 patients but have not been systematically evaluated. We performed a systematic literature review to identify all treatments reported to be administered to COVID-19 patients and to?assess time to clinically meaningful response for treatments with sufficient data. We searched PubMed, BioRxiv, MedRxiv, and ChinaXiv for articles reporting treatments for COVID-19 patients published between 1 December 2019 and 27 March 2020. Data were analyzed descriptively. Of the 2706 articles identified, 155 studies met the inclusion criteria, comprising 9152 patients. The cohort was 45.4% female and 98.3% hospitalized, and mean (SD) age was 44.4?years (SD 21.0). The most frequently administered drug classes were antivirals, antibiotics, and corticosteroids, and of the 115 reported drugs, the most frequently administered was combination lopinavir/ritonavir, which was associated with a time to clinically meaningful response (complete symptom resolution or hospital discharge) of 11.7 (1.09) days. There were insufficient data to compare across treatments. Many treatments have been administered to the first 9152 reported cases of COVID-19. These data serve as the basis for an open-source registry of all reported treatments given to COVID-19 patients?at www.CDCN.org/CORONA . Further work is needed to prioritize drugs for investigation in well-controlled clinical trials and treatment protocols.
机译:SARS-COV-2/2019新的冠状病毒(Covid-19)的出现创造了全球大流行,没有经批准的治疗或疫苗。许多治疗已经给Covid-19患者施​​用,但尚未系统地评估。我们进行了系统的文献综述,以识别报告的所有治疗据报告给Covid-19患者,并进行评估时间对具有足够数据的治疗的临床有意义的反应。我们搜索了Pubmed,Biorxiv,Medrxiv和Chinaxif,为2019年12月1日发表的Covid-19患者的文章报告治疗方法。描述了描述的数据。在确定的2706篇文章中,155项研究达到了包含9152名患者的含有标准。队列的女性为45.4%,98.3%住院,平均值(SD)年龄为44.4年(SD 21.0)。最常见的药物课程是抗病毒,抗生素和皮质类固醇,并且115个报告的药物,最常施用的是洛诺比罗/丽押人士,这与临床有意义的反应(完全症状分辨率或医院排放)相关联11.7(1.09)天。有足够的数据来比较治疗。已经向第一9152例报告的Covid-19病例施用了许多疗法。这些数据作为对Covid-19患者的所有报告治疗的开源注册表的基础?在www.cdcn.org/corona。需要进一步的工作来优先考虑良好控制临床试验和治疗方案的调查。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号